Literature DB >> 27667331

A paper-based immunoassay to determine HPV vaccination status at the point-of-care.

Benjamin D Grant1, Chelsey A Smith2, Philip E Castle3, Michael E Scheurer4, Rebecca Richards-Kortum5.   

Abstract

OBJECTIVE: To develop and evaluate a paper-based point-of-care HPV serology test to determine if an individual has received two or more HPV immunizations.
METHODS: The paper-based immunoassay was constructed using a nitrocellulose lateral flow strip with adsorbed HPV16 virus-like particles serving as the capturing moiety. Three capture zones containing virus-like particles were placed in series to allow for visual discrimination between high and low HPV16 plasma antibody concentrations. A plasma separation membrane was used to allow whole blood to be applied directly to the assay. All reagents were dried on glass fiber pads during device fabrication and were rehydrated with buffer at the time of use. A pilot study consisting of 35 subjects with a history of zero, one, two or three HPV vaccines was conducted to evaluate the immunoassay. The completed paper-based immunoassays were scanned for visual interpretation by three researchers who were blinded to the true results and separately evaluated quantitatively using MATLAB.
RESULTS: For the 28 tests valid for analysis, fifteen subjects reported receiving two or more HPV vaccines, three reported receiving one, and ten reported having no HPV vaccinations. The paper-based immunoassays for all fifteen subjects who reported having received two or more HPV vaccines were judged positive by all researchers. Twelve of the thirteen tests from individuals reporting one or zero vaccinations were deemed negative by all observers. One test from an unvaccinated individual was judged positive by two out of three reviewers. Quantitatively, all tests were correctly separated between the two groups.
CONCLUSIONS: We successfully designed and tested a HPV serology test amenable to the point-of-care. The device showed promising results in a pilot study for discriminating between those who received two or more HPV vaccinations and those who did not. Furthermore, this device offers a platform for producing other semi-quantitative point-of-care serological tests.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  HPV; Point-of-care testing; Serologic tests

Mesh:

Substances:

Year:  2016        PMID: 27667331      PMCID: PMC5075515          DOI: 10.1016/j.vaccine.2016.09.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

1.  Maturation of papillomavirus capsids.

Authors:  Christopher B Buck; Cynthia D Thompson; Yuk-Ying S Pang; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

2.  Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.

Authors:  Luisa L Villa; Kevin A Ault; Anna R Giuliano; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Darron R Brown; Alex Ferenczy; Diane M Harper; Laura A Koutsky; Robert J Kurman; Matti Lehtinen; Christian Malm; Sven-Eric Olsson; Brigitte M Ronnett; Finn Egil Skjeldestad; Margareta Steinwall; Mark H Stoler; Cosette M Wheeler; Frank J Taddeo; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Rocio Marchese; Mark T Esser; Janine Bryan; Kathrin U Jansen; Heather L Sings; Gretchen M Tamms; Alfred J Saah; Eliav Barr
Journal:  Vaccine       Date:  2006-05-15       Impact factor: 3.641

Review 3.  Chapter 8: Screening for cervical cancer in developing countries.

Authors:  Lynette Denny; Michael Quinn; R Sankaranarayanan
Journal:  Vaccine       Date:  2006-08-31       Impact factor: 3.641

4.  Self-report compared to electronic medical record across eight adult vaccines: do results vary by demographic factors?

Authors:  S J Rolnick; E D Parker; J D Nordin; B D Hedblom; F Wei; T Kerby; J M Jackson; A L Crain; G Euler
Journal:  Vaccine       Date:  2013-06-24       Impact factor: 3.641

5.  Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months.

Authors:  Eduardo Lazcano-Ponce; Margaret Stanley; Nubia Muñoz; Leticia Torres; Aurelio Cruz-Valdez; Jorge Salmerón; Rosalba Rojas; Rolando Herrero; Mauricio Hernández-Ávila
Journal:  Vaccine       Date:  2013-12-16       Impact factor: 3.641

6.  Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.

Authors:  Jean-François Laprise; Mélanie Drolet; Marie-Claude Boily; Mark Jit; Chantal Sauvageau; Eduardo L Franco; Philippe Lemieux-Mellouki; Talía Malagón; Marc Brisson
Journal:  Vaccine       Date:  2014-08-12       Impact factor: 3.641

7.  Installing and implementing a computer-based patient record system in sub-Saharan Africa: the Mosoriot Medical Record System.

Authors:  Joseph K Rotich; Terry J Hannan; Faye E Smith; John Bii; Wilson W Odero; Nguyen Vu; Burke W Mamlin; Joseph J Mamlin; Robert M Einterz; William M Tierney
Journal:  J Am Med Inform Assoc       Date:  2003-03-28       Impact factor: 4.497

8.  A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.

Authors:  Elmar A Joura; Anna R Giuliano; Ole-Erik Iversen; Celine Bouchard; Constance Mao; Jesper Mehlsen; Edson D Moreira; Yuen Ngan; Lone Kjeld Petersen; Eduardo Lazcano-Ponce; Punnee Pitisuttithum; Jaime Alberto Restrepo; Gavin Stuart; Linn Woelber; Yuh Cheng Yang; Jack Cuzick; Suzanne M Garland; Warner Huh; Susanne K Kjaer; Oliver M Bautista; Ivan S F Chan; Joshua Chen; Richard Gesser; Erin Moeller; Michael Ritter; Scott Vuocolo; Alain Luxembourg
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

9.  Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes.

Authors:  C Leder; J A Kleinschmidt; C Wiethe; M Müller
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

10.  Comparison of antibody responses to human papillomavirus vaccination as measured by three assays.

Authors:  Hilary A Robbins; Troy J Kemp; Carolina Porras; Ana Cecilia Rodriguez; Mark Schiffman; Sholom Wacholder; Paula Gonzalez; John Schiller; Douglas Lowy; Sylviane Poncelet; Mark Esser; Katie Matys; Allan Hildesheim; Ligia A Pinto; Rolando Herrero; Mahboobeh Safaeian
Journal:  Front Oncol       Date:  2014-01-13       Impact factor: 6.244

View more
  3 in total

1.  Rapid immunodiagnostics of multiple viral infections in an acoustic microstreaming device with serum and saliva samples.

Authors:  Neha Garg; Dylan Boyle; Arlo Randall; Andy Teng; Jozelyn Pablo; Xiaowu Liang; David Camerini; Abraham P Lee
Journal:  Lab Chip       Date:  2019-04-23       Impact factor: 6.799

2.  Development of Low-Cost Point-of-Care Technologies for Cervical Cancer Prevention Based on a Single-Board Computer.

Authors:  Sonia Parra; Eduardo Carranza; Jackson Coole; Brady Hunt; Chelsey Smith; Pelham Keahey; Mauricio Maza; Kathleen Schmeler; Rebecca Richards-Kortum
Journal:  IEEE J Transl Eng Health Med       Date:  2020-02-03       Impact factor: 3.316

Review 3.  From potential to practice: how accelerating access to HPV tests and screen and treat programmes can help eliminate cervical cancer.

Authors:  William Cherniak; Nikki Tyler; Kriti Arora; Ilana Lapidos-Salaiz; Emma Sczudlo; Amy Lin; Matthew Barnhart; John Flanigan; Shannon Silkensen
Journal:  Fam Med Community Health       Date:  2019-10-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.